3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
3
Melanoma
3
Lung Neoplasms
3
Glioma
3
Thyroid Carcinoma, Anaplastic
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sexual Dysfunction, Physiological
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Melanoma, Cutaneous Malignant
1
Lymphoproliferative Disorders
1
Lymphoma
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Gastrointestinal Neoplasms
1
Interventions
Surveys and Questionnaires
5
Nivolumab
5
pembrolizumab
3
atezolizumab
3
Radiosurgery
3
pralsetinib
2
pertuzumab
2
cobimetinib
2
cemiplimab
2
amminedichloro(2-methylpyridine)platinum(II)
2
alectinib
2
Magnetic Resonance Spectroscopy
2
Exercise
2
Drug Therapy
2
trastuzumab deruxtecan
1
trametinib
1
tepotinib
1
talazoparib
1
selpercatinib
1
repotrectinib
1
remune
1
ponatinib
1
pemigatinib
1
pazopanib
1
palbociclib
1
osimertinib
1
motexafin gadolinium
1
montanide ISA 51
1
itacitinib
1
ipatasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
dabrafenib
×
Thoracic
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled